Blood test for the diagnosis of bipolar disorders available in France from April 1

A blood test for the detection of bipolar disorders, available in France from April 1

From April 1, a blood test to diagnose bipolar disorder will be available on French soil. This significant progress in mental health offers new hope for patients suffering from these disorders and their loved ones.

Early detection of bipolar disorders: a significant advance

THE bipolar disorder, a chronic and disabling condition, affects approximately 1% to 2.5% of the world's population. Often, the diagnosis is late, the affected person can go several years without being diagnosed, thus worsening the impact of the disease on their quality of life. The symptoms of bipolar disorder can be confused with those of other mental illnesses, such as depression. Hence the crucial importance of a diagnostic test that is easy to implement and precise. From April 1, such a test, based on a simple blood test, will be available in France.

The blood test: a technological feat

Universally practiced and non-invasive, blood testing provides access to a multitude of information on an individual's state of health. The blood test to detect bipolar disorders represents a major advance since it will allow early, rapid and accurate diagnosis. The way this test works is based on the identification of specific markers present in the blood of people suffering from bipolar disorder. Its development is the result of many years of research in neuroscience and psychiatry.

Access to appropriate treatment more quickly

The main advantage of this blood test is that it will allow affected people to access appropriate treatment more quickly. Indeed, once the disorder is diagnosed, the doctor can prescribe appropriate therapy, thus helping to improve the quality of life of patients. In conclusion, the arrival in France of this blood test to diagnose bipolar disorder from April 1 marks an important advance in the management of this disease. It will allow earlier diagnosis, thus reducing the time to access treatment and strengthening the chances of better management of the disease.